NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.50
  • Forecasted Upside: 50.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.02 (-1.96%)

This chart shows the closing price for ADMP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adamis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMP

Analyst Price Target is $1.50
▲ +50.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Adamis Pharmaceuticals in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 50.00% upside from the last price of $1.00.

This chart shows the closing price for ADMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Adamis Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2021Maxim GroupReiterated RatingHoldLow
11/16/2020Maxim GroupDowngradeBuy ➝ HoldHigh
9/23/2020Maxim GroupReiterated RatingBuy$1.50High
8/24/2020Dawson JamesDowngradeBuy ➝ NeutralMedium
8/19/2020Raymond JamesReiterated RatingHoldLow
6/16/2020Maxim GroupReiterated RatingBuy$1.50Low
6/15/2020Dawson JamesUpgradeBuy$1.00Medium
5/13/2020Maxim GroupUpgradeHold ➝ Buy$1.50High
2/27/2020Dawson JamesDowngradeBuy ➝ NeutralHigh
11/26/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
11/25/2019Maxim GroupDowngradeBuy ➝ HoldN/A
8/9/2019Maxim GroupSet Price TargetBuy$6.00High
7/23/2019B. RileyUpgradeSell ➝ NeutralLow
7/16/2019B. RileyDowngradeNeutral ➝ Sell$1.90 ➝ $1.10Low
7/2/2019Dawson JamesInitiated CoverageBuyMedium
5/10/2019Raymond JamesSet Price TargetBuy$4.00High
3/19/2019Maxim GroupSet Price TargetBuy$10.00Low
12/7/2018Maxim GroupSet Price TargetBuy$10.00Low
11/13/2018HC WainwrightSet Price TargetBuy$7.00Medium
11/12/2018B. RileyDowngradeBuy ➝ Neutral$7.50 ➝ $2.50High
9/28/2018HC WainwrightSet Price TargetBuy$7.00High
9/12/2018Maxim GroupReiterated RatingBuy$13.00Low
9/10/2018HC WainwrightSet Price TargetBuy$7.00Medium
8/23/2018HC WainwrightReiterated RatingBuyLow
7/3/2018B. RileyBoost Price TargetBuy$7.50High
7/2/2018Maxim GroupBoost Price TargetBuy$13.00High
7/2/2018HC WainwrightReiterated RatingBuy$10.00High
5/14/2018HC WainwrightSet Price TargetBuy$7.00High
5/11/2018Maxim GroupBoost Price TargetBuy ➝ Buy$5.00 ➝ $10.00Low
4/23/2018HC WainwrightInitiated CoverageBuy$7.00High
3/23/2018B. RileyBoost Price TargetBuy ➝ Buy$6.25 ➝ $7.50Low
3/19/2018Maxim GroupSet Price TargetBuy$5.00High
3/14/2018B. RileyReiterated RatingBuyMedium
3/6/2018Maxim GroupSet Price TargetBuy$5.00High
2/23/2018Raymond JamesSet Price TargetBuy$7.00High
2/23/2018Maxim GroupSet Price TargetBuy$5.00High
2/14/2018Maxim GroupSet Price TargetBuy$5.00Low
12/5/2017Maxim GroupSet Price TargetBuy ➝ Buy$14.00Medium
11/30/2017B. RileySet Price TargetBuy$10.00Medium
11/15/2017B. RileySet Price TargetBuy$10.00N/A
10/4/2017B. RileyReiterated RatingBuy ➝ Buy$9.50Low
9/12/2017Raymond JamesInitiated CoverageOutperform$7.00High
8/21/2017Maxim GroupReiterated RatingBuy$13.00High
6/12/2017Maxim GroupReiterated RatingBuy$10.00Low
3/23/2017Maxim GroupReiterated RatingBuy$10.00High
1/25/2017Maxim GroupReiterated RatingBuy$10.00N/A
1/24/2017B. RileyReiterated RatingBuy$5.00N/A
1/19/2017B. RileyReiterated RatingBuy$5.00N/A
1/19/2017Maxim GroupSet Price TargetBuy$10.00N/A
12/24/2016B. RileyInitiated CoverageBuy$5.00N/A
12/20/2016Maxim GroupSet Price TargetBuy$10.00N/A
12/19/2016B. RileyInitiated CoverageBuy$5.00N/A
10/30/2016Maxim GroupSet Price TargetBuy$10.00N/A
9/19/2016Maxim GroupSet Price TargetBuy$10.00N/A
8/29/2016Maxim GroupReiterated RatingBuy$10.00N/A
(Data available from 7/26/2016 forward)
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.00
Low: $0.99
High: $1.03

50 Day Range

MA: $0.96
Low: $0.67
High: $1.23

52 Week Range

Now: $1.00
Low: $0.38
High: $2.34


28,558 shs

Average Volume

12,927,522 shs

Market Capitalization

$148.89 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Adamis Pharmaceuticals?

The following equities research analysts have issued research reports on Adamis Pharmaceuticals in the last year: Dawson James, Maxim Group, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for ADMP.

What is the current price target for Adamis Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Adamis Pharmaceuticals in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 45.6%. Maxim Group has the highest price target set, predicting ADMP will reach $1.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $1.50 for Adamis Pharmaceuticals in the next year.
View the latest price targets for ADMP.

What is the current consensus analyst rating for Adamis Pharmaceuticals?

Adamis Pharmaceuticals currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ADMP, but not buy more shares or sell existing shares.
View the latest ratings for ADMP.

What other companies compete with Adamis Pharmaceuticals?

How do I contact Adamis Pharmaceuticals' investor relations team?

Adamis Pharmaceuticals' physical mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company's listed phone number is 858-997-2400 and its investor relations email address is [email protected] The official website for Adamis Pharmaceuticals is